LOGO

Checklist: A COVID-19 Treatment That Can’t Be Overlooked

Eli Lilly says their monoclonal antibody therapy promises real help, not just hope.
Posted on Dec 5, 2021 | 03:00pm
Spotlight | Brought to you by Watch

As the race to vaccinate continues, Eli Lilly and Company want COVID-19 patients with mild-to-moderate symptoms to be aware that their monoclonal antibody therapy, granted Emergency Use Authorization by the U.S. FDA, can help minimize symptoms and decrease the need for hospitalization. Of particular importance, they say, is for those at risk for serious COVID-19 complications to discuss the possibility of monoclonal antibody use with their healthcare providers. Many people, they maintain, are not aware that they’re eligible for the treatments. 

Administered via a one-time IV infusion, monoclonal antibody treatments are typically given at an infusion center, clinic, or hospital (though not to patients who’ve been admitted). They should be given as soon as possible, says Eli Lilly, and within 10 days of the onset of symptoms. Those considered at risk for developing serious COVID-19 complications include people with diabetes or heart disease, those who are immunosuppressed or obese, and those over age 65. 

Talk to your doctor to find out if Eli Lilly’s monoclonal antibody therapy is right for you. To learn more, visit combatcovid.hhs.gov.

If looking for where to find monoclonal antibody treatments to fight COVID-19, visit the National Infusion Center’s COVID-19 website or the U.S. Health & Human Services therapeutics distribution website

Photo Credit: Courtesy of Eli Lilly